Eaby sandy beth (19 résultats)
- Couverture rigide
Vendeur : Universitätsbuchhandlung Herta Hold GmbH, Berlin, AllemagneUniversitätsbuchhandlung Herta Hold GmbH
Contacter le vendeurVendeur avec une évaluation de 4 étoilesEtat: Occasion
EUR 15,00
EUR 30,00 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 4 disponible(s)
V, 120 p. Hardcover. Versand aus Deutschland / We dispatch from Germany via Air Mail. Einband bestoßen, daher Mängelexemplar gestempelt, sonst sehr guter Zustand. Imperfect copy due to slightly bumped cover, apart from this in very good condition. Stamped. Sprache: Englisch.
- Couverture rigide
Vendeur : Books Puddle, New York, NY, Etats-UnisBooks Puddle
Contacter le vendeurVendeur avec une évaluation de 4 étoilesEtat: Neuf
EUR 85,05
EUR 3,44 expéditionExpédition nationale : Etats-UnisQuantité disponible : 4 disponible(s)
Etat : New. pp. 120.
- Couverture souple
Vendeur : Books Puddle, New York, NY, Etats-UnisBooks Puddle
Contacter le vendeurVendeur avec une évaluation de 4 étoilesEtat: Neuf
EUR 85,95
EUR 3,44 expéditionExpédition nationale : Etats-UnisQuantité disponible : 4 disponible(s)
Etat : New. pp. 120 2019th edition NO-PA16APR2015-KAP.
- Couverture souple
Vendeur : AHA-BUCH GmbH, Einbeck, AllemagneAHA-BUCH GmbH
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 58,87
EUR 30,50 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 1 disponible(s)
Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - This book aims to educate nurses and advanced practice providers (APP's) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the…scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP's are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents.Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers.To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP's with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the nextlevel of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations.With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.
Langue : anglais
Edité par Springer International Publishing, Springer International Publishing, 2019
- Couverture rigide
Vendeur : AHA-BUCH GmbH, Einbeck, AllemagneAHA-BUCH GmbH
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 53,49
EUR 61,95 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 1 disponible(s)
Buch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - This book aims to educate nurses and advanced practice providers (APP's) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope o…f therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP's are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents.Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers.To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP's with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the nextlevel of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations.With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.
- Couverture souple
Vendeur : preigu, Osnabrück, Allemagnepreigu
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 50,45
EUR 70,00 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 5 disponible(s)
Taschenbuch. Etat : Neu. Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners | Marianne Davies (u. a.) | Taschenbuch | v | Englisch | 2020 | Springer | EAN 9783030165529 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]spring…er[dot]com | Anbieter: preigu.
- Couverture souple
Vendeur : Buchpark, Trebbin, AllemagneBuchpark
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Occasion
EUR 44,10
EUR 105,00 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 1 disponible(s)
Etat : Hervorragend. Zustand: Hervorragend | Sprache: Englisch | Produktart: Bücher | This book aims to educate nurses and advanced practice providers (APP¿s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners ab…out the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP¿s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP¿s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the nextlevel of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.
- Couverture rigide
- impression à la demande
Vendeur : Brook Bookstore On Demand, Napoli, NA, ItalieBrook Bookstore On Demand
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 46,22
EUR 5,50 expéditionExpédition depuis Italie vers Etats-UnisQuantité disponible : Plus de 20 disponibles
Etat : new. Questo è un articolo print on demand.
- Couverture souple
- impression à la demande
Vendeur : Brook Bookstore On Demand, Napoli, NA, ItalieBrook Bookstore On Demand
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 46,22
EUR 5,50 expéditionExpédition depuis Italie vers Etats-UnisQuantité disponible : Plus de 20 disponibles
Etat : new. Questo è un articolo print on demand.
Langue : anglais
Edité par Springer International Publishing Jul 2019, 2019
- Couverture rigide
- impression à la demande
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, AllemagneBuchWeltWeit Ludwig Meier e.K.
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 53,49
EUR 23,00 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 2 disponible(s)
Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book aims to educate nurses and advanced practice providers (APP's) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners a…bout the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP's are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents.Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers.To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP's with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations.With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment. 128 pp. Englisch.
Langue : anglais
Edité par Springer International Publishing Aug 2020, 2020
- Couverture souple
- impression à la demande
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, AllemagneBuchWeltWeit Ludwig Meier e.K.
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 53,49
EUR 23,00 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 2 disponible(s)
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book aims to educate nurses and advanced practice providers (APP's) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practiti…oners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP's are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents.Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers.To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP's with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations.With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment. 128 pp. Englisch.
- Couverture rigide
- impression à la demande
Vendeur : Majestic Books, Hounslow, Royaume-UniMajestic Books
Contacter le vendeurVendeur avec une évaluation de 4 étoilesEtat: Neuf
EUR 85,10
EUR 7,56 expéditionExpédition depuis Royaume-Uni vers Etats-UnisQuantité disponible : 4 disponible(s)
Etat : New. Print on Demand pp. 120.
- Couverture souple
- impression à la demande
Vendeur : Majestic Books, Hounslow, Royaume-UniMajestic Books
Contacter le vendeurVendeur avec une évaluation de 4 étoilesEtat: Neuf
EUR 85,83
EUR 7,56 expéditionExpédition depuis Royaume-Uni vers Etats-UnisQuantité disponible : 4 disponible(s)
Etat : New. Print on Demand pp. 120.
- Couverture souple
- impression à la demande
Vendeur : moluna, Greven, Allemagnemoluna
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 47,23
EUR 48,99 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : Plus de 20 disponibles
Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Very first book directed to nursingInforms on how driver mutations drive treatment decisions in NSCLC and the application to care of patients Provide nurses with the tools to educate patients about how to partner.
- Couverture rigide
- impression à la demande
Vendeur : moluna, Greven, Allemagnemoluna
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 47,23
EUR 48,99 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : Plus de 20 disponibles
Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Very first book directed to nursingInforms on how driver mutations drive treatment decisions in NSCLC and the application to care of patients Provide nurses with the tools to educate patients about how to partner.
- Couverture rigide
- impression à la demande
Vendeur : Biblios, frankfurt am main, HESSE, AllemagneBiblios
Contacter le vendeurVendeur avec une évaluation de 4 étoilesEtat: Neuf
EUR 87,42
EUR 9,95 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 4 disponible(s)
Etat : New. PRINT ON DEMAND pp. 120.
- Couverture souple
- impression à la demande
Vendeur : Biblios, frankfurt am main, HESSE, AllemagneBiblios
Contacter le vendeurVendeur avec une évaluation de 4 étoilesEtat: Neuf
EUR 88,08
EUR 9,95 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 4 disponible(s)
Etat : New. PRINT ON DEMAND pp. 120.
- Couverture souple
- impression à la demande
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagnebuchversandmimpf2000
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 53,49
EUR 60,00 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 1 disponible(s)
Taschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Is the first book that is directed to nursingSpringer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 128 pp. Englisch.
- Couverture rigide
- impression à la demande
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagnebuchversandmimpf2000
Contacter le vendeurVendeur avec une évaluation de 5 étoilesEtat: Neuf
EUR 53,49
EUR 60,00 expéditionExpédition depuis Allemagne vers Etats-UnisQuantité disponible : 1 disponible(s)
Buch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Is the first book that is directed to nursingSpringer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 128 pp. Englisch.
